Biomerica Reports Fiscal 2024 Year-End Results
Total Revenue Grows 1% Year-Over-Year – Core Revenue Excluding COVID Tests Rises 5%, Indicating Stronger Growth
Major Cost Savings Plan Launched After Year-End – Anticipated to Cut Expenses by $1.0 to $1.4 Million in the Coming Year
inFoods IBS Pilot with Large 1,100 Physician Group Progressing Ahead of Schedule
Biomerica, Inc. (NASDAQ: BMRA) has announced its financial results for the fiscal year that ended on May 31, 2024. The company saw a modest rise in net sales, reaching $5.4 million compared to $5.3 million the previous year. This increase is largely due to the high demand for EZ Detect™ colorectal screening tests and Aware® breast self-exam products.
Excluding revenues from COVID-19 test kits, Biomerica experienced a 5% year-over-year growth, highlighting the strength and resilience of its diverse product lineup. Additionally, the company improved its gross margin from 8% to 11%, thanks to better cost management and operational efficiencies.
Moreover, Biomerica successfully reduced its net loss for the fiscal year to $6.0 million, a 15% improvement from the $7.1 million net loss reported in fiscal 2023. This positive trend reflects the company’s ongoing commitment to effective expense management. After the fiscal year concluded, Biomerica initiated a substantial cost-saving plan expected to lower expenses by $1.0 million to $1.4 million in the upcoming year.
Overview of Revenue Performance
Looking at Biomerica’s revenue performance, the company achieved total revenues of $5.4 million for the fiscal year, which is a slight increase from last year’s $5.3 million. The growth in revenue, especially in core product lines, underscores Biomerica's strategic focus on expanding its product offerings and sales channels.
The operational enhancements have also played a role in improving the gross margin, which is essential for maintaining profitable growth in a competitive market.
Strategic Growth Areas for Biomerica
Biomerica is concentrating on three key areas to foster future revenue growth:
- EZ Detect™ and Other At-Home Tests in the MENA Region: The company aims to broaden its reach in the Middle East and North Africa through strategic distribution partnerships while actively pursuing insurance reimbursement opportunities.
- H. pylori Antigen Sales in the U.S: Biomerica is seizing market opportunities related to the Hp Detect™ Stool Antigen ELISA test, which has shown promise in U.S. markets.
- inFoods® IBS Opportunities: The company is working to increase the adoption of inFoods® IBS tests among physician groups and explore potential distribution partnerships.
Key Milestones Achieved in Fiscal Year 2024
FDA 510(k) Clearance: Biomerica received FDA clearance for its Hp Detect™ Stool Antigen ELISA test, which is essential for the early detection and treatment of gastrointestinal issues caused by H. pylori bacteria.
Advancement of inFoods® IBS: The company made notable progress with a new patient self-collection system for the inFoods® IBS diagnostic test, significantly improving its accessibility and reach.
Exclusive Distribution Agreement: Biomerica secured a multi-year exclusive distribution agreement with a major healthcare conglomerate in the UAE, aimed at enhancing the availability of its at-home screening products.
Commitment to Innovation
Through these initiatives, Biomerica remains committed to strengthening its financial position and driving long-term growth through innovative medical products and strategic partnerships.
Frequently Asked Questions
What were Biomerica's total revenues for fiscal 2024?
Biomerica reported total revenues of $5.4 million for fiscal 2024, a slight increase from $5.3 million in the previous fiscal year.
What initiatives is Biomerica implementing for cost-saving?
The company is implementing a significant cost-saving plan that is projected to reduce expenses by $1.0 million to $1.4 million in the upcoming year.
What products contributed to Biomerica's revenue growth?
Revenue growth was primarily driven by strong demand for products such as EZ Detect™ colorectal screening tests and Aware® breast self-exam products.
What strategic areas is Biomerica focusing on?
Biomerica is focusing on expanding its market for EZ Detect™ tests, enhancing H. pylori antigen sales, and increasing the utilization of inFoods® IBS tests.
What key approvals has Biomerica received recently?
Biomerica has received FDA 510(k) clearance for its Hp Detect™ Stool Antigen ELISA test, marking a significant milestone in its product offerings.
